Managing Pediatric Systemic Lupus Erythematosus in Thrombotic Thrombocytopenic Purpura
Researchers recommended performing lactate dehydrogenase level and blood smear testing in patients with renal and neurological symptoms.
All articles by Megan Garlapow, PhD
Rates of Transcript Variants in Chronic Myeloid Leukemia Associated With Sex and Age
Different fusion genes of BCR-ABL1 are all leukemogenic for acute lymphoblastic leukemia or chronic myeloid leukemia (CML). According to results published in Leukemia, the particular transcripts present in patients with CML are correlated with sex and age and are not constant worldwide. This study systematically assessed the frequency of these leukemogenic fusion genes in patients…
Hemolysis, Inflammation, and Iron Overload Characterize Congenital Hemolytic Anemias
Researchers assessed the predictive value of various laboratory parameters for iron overload in patients with congenital hemolytic anemias.
Clinical Outcomes in Philadelphia-Negative ALL With Inotuzumab Ozogamicin Plus Chemotherapy
Propensity score analysis showed that patients in the inotuzumab ozogamicin arm experienced significantly longer event-free and overall survival.
Immunoglobulin Lambda Translocations Suggest Inferior Prognosis in Newly Diagnosed Multiple Myeloma
Translocations of IgL occurred in approximately 10% of patients with newly diagnosed multiple myeloma.
Caplacizumab Associated With Improved Outcomes in Acquired Thrombotic Thrombocytopenic Purpura
Patients receiving caplacizumab experienced faster normalization of platelet count and fewer adverse events compared with patients on placebo.
Decreased Relapse, Mortality Rates With Rituximab in Acquired Thrombotic Thrombocytopenic Purpura
Researchers conducted a meta-analysis of 9 studies in patients receiving either rituximab or conventional treatment for TTP.
EBV Reactivation After Transplant Associated With Worse Clinical Outcomes in Myelodysplastic Syndrome
Patients who experienced reactivation of Epstein-Barr virus also experienced inferior relapse-free survival and increased incidence of relapse.
Improved Progression-Free Survival in Relapsed/Refractory Indolent Lymphoma With Lenalidomide Plus Rituximab
Patients with follicular or marginal zone lymphoma who received lenalidomide with rituximab experienced a median progression-free survival of 39.4 months.
No Correlation Between SF3B1 Mutation in Myelodysplastic Syndrome and Overall Survival
Results from a systematic review and meta-analysis published in Critical Reviews in Oncology/Hematology indicated there was no association between mutations in SF3B1 and overall survival (OS) in patients with myelodysplastic syndrome (MDS). Mutations in the SF3B1 gene are the most common mutations in MDS, though the prognostic implications of these mutations are unclear. In this…
Next post in Myelodysplastic Syndromes
